TrialThe oncologist2026

Identification of key symptoms impacting HRQOL in advanced renal cell carcinoma: nivolumab plus cabozantinib versus sunitinib in CheckMate 9ER.

Cristiane Bergerot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.